Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.70 |
| ▸ | RAB9A | P51151 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.65 |
| ▸ | TSHR | P16473 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1790357 | 0.82 | TP53 (1.00) | TP53RAB9AKMT2ATSHRALDH1A1 | |
| SCHEMBL4679461 | 0.82 | POLB (0.72) | TP53RAB9AKMT2ATSHRALDH1A1 | |
| SCHEMBL4581685 | 0.82 | TP53 (0.72) | TP53RAB9AKMT2ATSHRALDH1A1 | |
| SCHEMBL29928369 | 0.82 | TP53 (0.72) | TP53RAB9AKMT2ATSHRALDH1A1 | |
| SCHEMBL4582080 | 0.81 | TP53 (0.72) | TP53RAB9AKMT2ATSHRALDH1A1 | |
| SCHEMBL4592430 | 0.81 | TP53 (0.87) | TP53RAB9AKMT2ATSHRALDH1A1 | |
| SCHEMBL4581758 | 0.80 | TP53 (0.82) | TP53RAB9AKMT2ATSHRALDH1A1 | |
| SCHEMBL4581862 | 0.80 | TP53 (0.82) | TP53RAB9AKMT2ATSHRALDH1A1 | |
| SCHEMBL4583136 | 0.80 | TP53 (0.82) | TP53RAB9AKMT2ATSHRALDH1A1 | |
| SCHEMBL4581321 | 0.80 | TP53 (0.78) | TP53RAB9AKMT2ATSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362017-B2 | N-[5-chloro-2-(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide; antiproliferative agents; protein kinase inhibitors; drug screening | EXELIXIS, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-20080096892-A1 | C-Kit Modulators And Methods Of Use | EXELIXIS, INC. (US) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096892-A1 | C-Kit Modulators And Methods Of Use | KIT, PRKCH, PRKCB | TP53 1271/4885RAB9A 1443/4885KMT2A 1897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.